...
ALKSMID

Alkermes plc

HealthcareBiotechnology
$30.10
$0.01(-2.05%)
52W$25.17
$36.32
FinancialsValuationvs UTHR
Updated Mar 1, 12:00 AM
RSI39
RS Rating53/99
Beta0.61
Volatility36%
F-Score5/9
Mkt Cap$5.0B
EMERGING TREND

Price Action

5Y Daily
50 DMA150 DMA200 DMA

Technical Summary

EMERGING TREND

Alkermes plc shows underlying uptrend characteristics but has temporarily lost support at the 50-day moving average. Relative strength is moderate (RS Rating: 53), indicating performance broadly in line with the market. Earnings contraction of 67% provides fundamental context to the price action. Volume support will be critical for the stock to resolve this consolidation to the upside.

Relative Strength
53
out of 99
Average
Trend Score
3/4
Minervini Criteria
EMERGING TREND
Risk (Beta)
0.61
vs S&P 500
DEFENSIVE
52W Position
44%
from 52W low
Lower Half
Trend & Momentum Analysis

Trend Template (Minervini)

EMERGING TREND3/4 Criteria Met
CriterionValueStatus
Price > 50 SMA$31.47
50 SMA > 100 SMA$30.85
100 SMA > 150 SMA$29.98
150 SMA > 200 SMA$29.91

Price vs Moving Averages

PeriodValueSpreadSignal
20 SMA$33.16-9.24%BELOW
50 SMA$31.47-4.36%BELOW
100 SMA$30.85-2.43%BELOW
150 SMA$29.98+0.39%ABOVE
200 SMA$29.91+0.63%ABOVE

Price Performance

1D-2.1%
1W-6.5%
1M-11.2%
3M+1.8%
6M+4.0%
YTD+6.5%
1Y-12.3%
3Y+4.0%
52-Week Trading Range44% from low
$30.10
52W Low$25.17
52W High$36.32

Technical Indicators

RSI (14)BEARISH
39.0
305070
VCP ScoreCOOL
4/10
Base depth: 26.0%

Risk Profile

Beta
0.61
52W Vol
36%
ATR
$1.15
Max DD (1Y)
-26%

Volume Analysis

Today
30
50D Avg
1.58M
Vol Ratio
0.00x
Liquidity
MODERATE

Earnings Momentum

Q1'25-38%
$0.13
Q2'25-2%
$0.52
Q3'25-11%
$0.49
Q4'25-67%
$0.29
Fundamentals & Growth

Growth Trends

Compounded Sales Growth

10 Years:+8.91%
5 Years:+7.28%
3 Years:+9.90%
TTM:-5.25%

Compounded Profit Growth

10 Years:—
5 Years:—
3 Years:—
TTM:-34.10%

Stock Price CAGR

10 Years:-0.69%
5 Years:+9.41%
3 Years:+4.02%
1 Year:-12.32%

Return on Equity

10Y Avg:-1.4%
5Y Avg:11.0%
3Y Avg:24.6%
Last Year:13.3%

Key Metrics

Market Cap$5.0B
Gross Margin86.3%
Net Margin16.4%
Piotroski F-Score5/9

More ALKS Analysis

Full Financial AnalysisDCF & Intrinsic ValueTotal Return Calculator

Compare With

ALKS vs UTHRUTHRZLABAMRNADMA

Data Dictionary

RS Rating (Relative Strength)

Measures 12-month price performance vs all stocks. Rating of 53 meansALKS outperformed 53% of all stocks. Scores >80 indicate market leaders.

Beta

Measures volatility vs S&P 500. Beta of 0.61 means 39% less volatile than market.

Piotroski F-Score

9-point financial strength score based on profitability, leverage, and efficiency. Score of 5/9. Scores 7-9 = strong, 4-6 average, 0-3 = weak.

VCP (Volatility Contraction Pattern)

Measures base formation quality. Higher scores indicate tighter consolidation near pivot points. Score of 4/10 with COOL status.

Frequently Asked Questions

Is ALKS in an uptrend right now?

ALKS has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.

Is ALKS overbought or oversold?

ALKS's RSI (14) is 39. The stock is in neutral territory, neither overbought nor oversold.

Is ALKS outperforming the market?

ALKS has a Relative Strength (RS) Rating of 53 out of 99. ALKS is performing about average compared to the market.

Where is ALKS in its 52-week range?

ALKS is trading at $30.10, which is 83% of its 52-week high ($36.32) and 44% above its 52-week low ($25.17).

How volatile is ALKS?

ALKS has a Beta of 0.61 and 52-week volatility of 36%. It's less volatile than the S&P 500 - generally more stable.